$IMNM News

Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review

Immunome's New Drug Application For Desmoid Tumors Treatment Accepted By FDA, April 28, 2027 Assigned As Prescription Drug User Fee Act Target Action Date

Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target

Immunome Does First Participant In Its Phase 1 IM-1617 Study To Treat Solid Tumors

Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis

Truist Securities Maintains Buy on Immunome, Raises Price Target to $37

Barclays Initiates Coverage On Immunome with Overweight Rating, Announces Price Target of $36

HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target

Immunome Q1 EPS $(0.48) Beats $(0.57) Estimate

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome Submits New Drug Application To FDA For Varegacestat To Treat Desmoid Tumors, Backed By Phase 3 RINGSIDE Trial Showing 84% Reduction In Disease Progression Risk

A Look At Immunome (IMNM) Valuation As Varegacestat Nears ASCO 2026 Spotlight And FDA NDA Filing

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

Immunome Reveals Oral Presentation Of Phase 3 RINGSIDE Data At 2026 ASCO Annual Meeting

Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More

Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last?

Immunome: Upcoming NDA, Valuation, And Investment Case